Revenio Group Oyj

Director's Dealing • May 31, 2017

Disclosure 352908

Revenio Group Oyj - Managers' transactions

Revenio Group Corporation: Managers' transactions

Revenio Group Corporation, Managers' transactions, May 31, 2017 at 15:30 Revenio Group Corporation: Managers' transactions Person subject to the notification requirement Name: Karvo, Tomi Position: Other senior manager ------------------------------------------------------------------------------- Initial Notification Reference number: 743700I27E0FWSXLKK04_20170524134642_2 ------------------------------------------------------------------------------- Issuer Name: Revenio Group Oyj LEI: 743700I27E0FWSXLKK04 ------------------------------------------------------------------------------- Transaction details Transaction date: 2017-05-30 Nature of the Acceptance of a Stock Option transaction: Further details: Linked to stock option programme Instrument: Financial Instrument Linked to a Share or a Debt Instrument ISIN: FI4000261037 Volume: 5000 Unit price: Aggregated transactions Volume: 5000 Volume weighted average price: For further information, please contact: Robin Pulkkinen, CFO, +358 50 5059932 Distribution: Nasdaq Helsinki www.revenio.fi The Revenio Group in brief Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53.5% interest. The common denominators of Revenio's business operations include screening, follow- up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process. In 2016, Revenio Group's net sales totaled MEUR 23.4, with its operating profit for continuing operations standing at 30.1%. Revenio Group Corporation is listed on Nasdaq Helsinki. []